Dall'Olio R, Vaccheri A, Gandolfi O, Roncada P, Montanaro N
Institute of Pharmacology, University of Bologna, Italy.
Pharmacol Biochem Behav. 1988 Dec;31(4):941-4. doi: 10.1016/0091-3057(88)90409-1.
Rats were treated with a single large dose of various neuroleptic compounds and, 5-7 days after, they were assayed for either behavioral sensitivity to apomorphine (hypermotility and stereotyped behavior) or head-twitch response to the mixed serotonin-dopamine agonist quipazine. The animals withdrawn from chlorpromazine, fluphenazine, haloperidol, metoclopramide and the D1 selective blocker SCH 23390, showed enhanced hypermotility and/or stereotyped responses to apomorphine and reduced head-twitch response to quipazine. The rats withdrawn from thioridazine, (-)-sulpiride and sultopride responded to apomorphine only with enhanced hypermotility while their response to quipazine was either unchanged or even increased. The results are discussed in terms of dopaminergic brain areas and/or receptor subtypes involved in the modulation of the head-twitch response to quipazine. We concluded that an enhancement of dopaminergic tone at the striatal level could be related to the reduced head-twitch response to quipazine.
给大鼠单次注射大剂量的各种抗精神病化合物,5 - 7天后,检测它们对阿扑吗啡的行为敏感性(多动和刻板行为)或对5-羟色胺 - 多巴胺混合激动剂喹哌嗪的头部抽搐反应。停用氯丙嗪、氟奋乃静、氟哌啶醇、甲氧氯普胺和D1选择性阻断剂SCH 23390的动物,对阿扑吗啡表现出增强的多动和/或刻板反应,对喹哌嗪的头部抽搐反应减弱。停用硫利达嗪、(-)-舒必利和舒托必利的大鼠,仅对阿扑吗啡表现出增强的多动,而它们对喹哌嗪的反应未改变甚至增强。根据涉及调节对喹哌嗪头部抽搐反应的多巴胺能脑区和/或受体亚型对结果进行了讨论。我们得出结论,纹状体水平多巴胺能张力的增强可能与对喹哌嗪头部抽搐反应的减弱有关。